Drugs / Tricaprilin
Tricaprilin
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT05628636 | Nov → Dec 2022 | Alzheimer disease | Cerecin | Completed | No outcome recorded |
| Phase 1 | NCT05408780 | Jul → Aug 2022 | Alzheimer disease | Cerecin | Completed | No outcome recorded |
| Phase 1 | NCT04727970 | Nov 2021 → Dec 2023 | infantile spasms | Cerecin | Completed | No outcome recorded |
| Phase 1 | NCT05028114 | Aug 2021 → Mar 2022 | Alzheimer disease | Cerecin | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04268953 | Feb → Mar 2020 | Alzheimer disease | Cerecin | Completed | No outcome recorded |
| Phase 1 | NCT03971123 | Aug 2019 → Apr 2020 | Alzheimer disease | Cerecin | Completed | No outcome recorded |
| Phase 1 | NCT03635879 | Feb → Apr 2019 | Alzheimer disease | Cerecin | Withdrawn | No outcome recorded |
| Phase 1 | NCT03628352 | Sep 2018 → Aug 2019 | — | Cerecin | Completed | No outcome recorded |
| Phase 1 | NCT03551769 | Aug 2018 | Alzheimer disease | Cerecin | Completed | No outcome recorded |
| Phase 1 | NCT03063645 | Mar → Apr 2017 | — | Cerecin | Completed | No outcome recorded |
| Phase 1 | NCT02959710 | Nov 2016 → Feb 2017 | — | Cerecin | Completed | No outcome recorded |
| Phase 1 | NCT02833012 | Jul → Sep 2016 | — | Cerecin | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT01741194 | Mar 2013 → Oct 2016 | Alzheimer disease | Cerecin | Completed | Missed primary |
| Phase 2/3 | NCT01211782 | — | Alzheimer disease | Cerecin | Withdrawn | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT04437199 Comparator | Dec 2020 → Feb 2022 | migraine disorder | Cerecin | Completed | No outcome recorded |
| Phase 2 | NCT00355550 Comparator | Jul 2006 → Jun 2007 | — | Cerecin | Completed | No outcome recorded |
| Phase 2 | NCT00142805 Comparator | Nov 2004 → Jun 2006 | Alzheimer disease | Cerecin | Completed | No outcome recorded |
| Phase 3 | NCT05809908 Comparator | Dec 2026 → Jun 2029 expected | Alzheimer disease | Cerecin | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04187547 Comparator | Jun 2022 → Dec 2023 | Alzheimer disease | Cerecin | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tricaprilin | “This is an open-label, 3-arm study to compare tolerability of three different titration and dosing schedules of the AC-OLE-01-VA formulation of tricaprilin.” NCT05628636 ↗12“formulation of tricaprilin or matching placebo” NCT05408780 ↗ “Tricaprilin formulated as AC-1202” NCT05028114 ↗ |
| Known as | AC-1202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02959710 ↗ |
| Known as | AC-OLE-01-VA | “Daily Administration of Tricaprilin as AC-OLE-01-VA in Participants With Mild to Moderate Alzheimer's Disease Dementia” NCT05809908 ↗ |
| Known as | AC-SD-01 | “Tricaprilin formulated as AC-SD-01” NCT03551769 ↗ |
| Known as | caprylic triglyceride | “The AC-1204 formulation of caprylic triglyceride failed to improve cognition or functional ability in subjects with mild-to-moderate AD.” PMID 32310169 ↗ 2020 |
| Known as | CER-0001 | “Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study.” PMID 39094432 ↗ Jul 2024 |
| Modality | Other / unclassified | “tricaprilin, an MCT, demonstrated pharmacological activity” NCT00142805 ↗ |
| Route | Oral | “Tricaprilin formulation, once daily. Administered orally” NCT00142805 ↗ |